Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia

Author's Avatar
Nov 09, 2021

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its long-time partner, Dyamed Biotech Pte Ltd., announce a renewed and expanded long-term partnership for Singapore, Malaysia, Indonesia and Thailand for multiple indications using Sonoma’s patented Microcyn® Technology.